Chongqing - Chongqing's Liangjiang New Area recently signed a strategic partnership with Danaher Shanghai, launching the Danaher Western Innovation Center to boost medical innovation in the Chengdu-Chongqing region. This marks the Area's inaugural collaboration with a Fortune Global 500 pharmaceutical giant.

Liangjiang New Area signed a strategic cooperation agreement with Danaher Shanghai on March 31st. (Photo/Shu Ni)

The Danaher Western Innovation Center will serve as a hub for biopharmaceutical innovation and include functions such as talent development, research, innovation, customer service, technical support, and collaborative workspaces.

As part of the project, Danaher will establish a Life Science Research Institute, marking its third research institute in China, following Shanghai and Guangzhou. This institute will focus on pioneering advanced application methods for biopharmaceuticals and precision medicine.

Cytiva, part of Danaher and a leader in life sciences, will launch the Cytiva Western Science and Technology Innovation Center, focusing on biopharmaceutical technology, talent development, project incubation, and health economics. 

Both this center and the Danaher Western Innovation Center will act as open platforms for innovations in genomics, clinical evaluations, and areas like cell therapy. These efforts are designed to boost collaboration and enhance biopharmaceutical research and production quality locally.

The design sketch of Danaher Western Innovation Center. (Photo/Liangjiang New Area)

Beyond technological advancements, Danaher will utilize its Danaher Business System (DBS) to explore skills training and management projects for local enterprises in Chongqing.

Peng Yang, Global Vice President of Danaher and President of the China Region, expressed excitement about establishing a base of operations in Chongqing, a key western China region. He emphasized the firm's dedication to working with partners on an innovation platform for precision medicine and biopharmaceuticals.

Xu Hongqiu, Deputy Director of the Administrative Committee of Liangjiang New Area, highlighted the health industry as a crucial pillar and regional growth driver. Xu hopes Danaher's innovation platform contributes to building a complete research, experimentation, training, and incubation system.

Liangjiang New Area is home to 272 enterprises, making it the city's leading industrial hub. It has clusters in new drug R&D, high-end production, medical devices, and biotechnology. In 2023, its industrial output hit 15.158 billion yuan (about 2.09 billion U.S. dollars), with significant enterprises contributing 10.407 billion yuan, about 15.6% of the city's total industrial output.

Danaher, a leader in life sciences, medical diagnostics, and biotechnology, includes over 15 top market companies. Known for global innovation in life sciences and diagnostics, Danaher is key to tackling worldwide health issues.